Class 005: Biologics in the nature of cells for medical use, namely, covalent protein biologics; synthetic biology enabled covalent therapeutics and covalent peptide drugs and covalent protein drugs for the treatment of cancer, immune and inflammatory conditions, and metabolic diseases and disorders; libraries of covalent protein drugs and covalent peptide drugs for the treatment of cancer, immune and inflammatory conditions, and metabolic diseases and disorders; covalent antibodies for medical purposes; Class 042: Research and development in the field of covalent protein biologics; research and development of synthetic peptides containing covalent activation; research and development in the field of synthetic biology enabled covalent therapeutics and covalent peptide drugs and protein drugs; research and development for the purpose of selective covalent modification of peptides and proteins; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of covalent binding small-molecule and biologic therapeutics; research and development services for the purpose of engineering covalent antibodies
Class 005: Biologics in the nature of cells for medical use, namely, covalent protein biologics; synthetic biology enabled covalent therapeutics and covalent peptide drugs and covalent protein drugs for the treatment of cancer, immune and inflammatory conditions, and metabolic diseases and disorders; libraries of covalent protein drugs and covalent peptide drugs for the treatment of cancer, immune and inflammatory conditions, and metabolic diseases and disorders; covalent antibodies for medical purposes; Class 042: Research and development in the field of covalent protein biologics; research and development of synthetic peptides containing covalent activation; research and development in the field of synthetic biology enabled covalent therapeutics and covalent peptide drugs and protein drugs; research and development for the purpose of selective covalent modification of peptides and proteins; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of covalent binding small-molecule and biologic therapeutics; research and development services for the purpose of engineering covalent antibodies
Cookie Preferences
We use cookies (including Google Analytics) to improve our site and understand how visitors use it.
